Valeant Pharmaceuticals receives Complete Response Letter from the FDA
Valeant announced it has received a CRL from the FDA regarding the NDA for latanoprostene bunod ophthalmic solution, 0.024%, an intraocular pressure lowering single-agent eye drop for patients with open angle glaucoma. The FDA's letter did not identify any efficacy or safety concerns. July 22, 2016